> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Corvus Wants FDA Meeting on CPI-818 Trial
- URL: https://www.fdaweb.com/corvus-wants-fda-meeting-on-cpi-818-trial/
- Published: 2023-06-15T12:00:00.000Z
- Updated: 2026-09-14T18:39:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154696

Corvus Pharmaceuticals says it plans to meet with FDA officials in the third quarter to discuss a potential registration Phase 3 trial of its CPI-818 ITK inhibitor in T cell lymphoma. In a [statement](https://www.einnews.com/pr%5Fnews/639642774/corvus-pharmaceuticals-presents-new-cpi-818-interim-data-at-the-international-conference-on-malignant-lymphoma?ref=fdaweb.com) announcing updated CPI-818 Phase 1/1b results, the company says it is beginning to plan for clinical trials with CPI-818 monotherapy in solid tumors.

Corvus says the new data demonstrate the potential to treat a variety of solid and hematological cancers based on a novel immunotherapy method of action.